Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?

[1]  A. Hinman,et al.  Measles and Rubella Global Strategic Plan 2012-2020 midterm review. , 2018, Vaccine.

[2]  K. Lorenson,et al.  What vaccine product attributes do immunization program stakeholders value? Results from interviews in six low- and middle-income countries. , 2016, Vaccine.

[3]  N. Turner.  Meeting of the Strategic Advisory Group of Experts on immunization, October 2016 – conclusions and recommendations. , 2016, Releve epidemiologique hebdomadaire.

[4]  M. Diallo,et al.  Global Routine Vaccination Coverage, 2015. , 2016, MMWR. Morbidity and mortality weekly report.

[5]  M. Meltzer,et al.  Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development , 2016, Drugs in R&D.

[6]  M. Kendall,et al.  Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses , 2016, Scientific Reports.

[7]  M. Prausnitz,et al.  A microneedle patch containing measles vaccine is immunogenic in non-human primates. , 2015, Vaccine.

[8]  Ichiro Katayama,et al.  Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. , 2015, Biomaterials.

[9]  Shawn T. Brown,et al.  Costs of vaccine programs across 94 low- and middle-income countries. , 2015, Vaccine.

[10]  Hiromasa Okayasu,et al.  Affordable inactivated poliovirus vaccine: strategies and progress. , 2014, The Journal of infectious diseases.

[11]  M. Prausnitz,et al.  Measles vaccination using a microneedle patch. , 2013, Vaccine.

[12]  C. Bauch,et al.  Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. , 2011, The Journal of infectious diseases.

[13]  Mark R. Prausnitz,et al.  Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.

[14]  Dexiang Chen,et al.  Desirable attributes of vaccines for deployment in low-resource settings. , 2013, Journal of pharmaceutical sciences.

[15]  J. Bland,et al.  Protecting the world's children: the story of WHO's immunization programme. , 1998, World health forum.